Liraglutide: uses, research, and availability

What is Liraglutide?

Liraglutide is a GLP-1 receptor agonist taken as a once-daily injection. It is FDA-approved as Victoza for type 2 diabetes and as Saxenda for chronic weight management.

Saxenda is also approved for certain eligible adolescents aged 12 and older for weight management, in addition to adults.

How it is thought to work

Like other GLP-1 medications, liraglutide reduces appetite, slows stomach emptying, and supports the body's insulin response, helping lower calorie intake and improve blood-sugar control.

What the research shows

Liraglutide has a long clinical track record. The LEADER trial reported cardiovascular benefit in people with type 2 diabetes, and weight-management trials supported its use for chronic weight control alongside lifestyle change.

Approved uses

• Chronic weight management in eligible adults and certain adolescents (per approved use)
• Blood-sugar control in type 2 diabetes
• Cardiovascular risk reduction in eligible patients

Availability

Liraglutide is FDA-approved and available now by prescription. It does not depend on the 2026 peptide review.

How to access Liraglutide legitimately

A licensed provider reviews your eligibility and prescribes the branded product. Liraglutide is a daily injection, which some patients prefer and others find less convenient than weekly options.

PeptideForward can match you with vetted telehealth providers who handle these therapies through legitimate channels. The eligibility check takes about five minutes and there is no cost to see if you are a candidate.

Frequently asked questions

How is it different from weekly GLP-1s? Liraglutide is dosed daily rather than weekly. Your provider can discuss whether a daily or weekly medication fits your routine and goals.

Is it legal now? Yes. It is FDA-approved and prescribable today for patients who qualify.

Does PeptideForward sell it? No. We are an education and matching service only.